10.05.2022 - New clinical results from MORNINGSKY trial shows 71% reduction in hospitalization (secondary endpoint) in broad patient population with COVID-19 treated with bemnifosbuvir (AT-527) versus placebo (p=0.047, unadjusted, exploratory) New clinical .
USAID Supports Legal Analysis of Strategic Reforms in Uzbekistan usembassy.gov - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from usembassy.gov Daily Mail and Mail on Sunday newspapers.